Nothing exciting. It is nice to see a little more detail on the general met testing strategy and scope split between ANSTO, Simulus and IMO. It's taking a while, but if it means we're going to get comprehensive results across a range of variables then I'm happy to wait.
Ann: Quarterly Activities/Appendix 5B Cash Flow Report, page-2
Add MRD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.785M | |||
| Open | High | Low | Value | Volume |
| 0.1¢ | 0.1¢ | 0.1¢ | $6.57K | 6.570M |
| MRD (ASX) Chart |
